{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:01:29Z","timestamp":1761217289027},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,6,29]],"date-time":"2009-06-29T00:00:00Z","timestamp":1246233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2407-9-212","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T06:15:20Z","timestamp":1246342520000},"source":"Crossref","is-referenced-by-count":47,"title":["Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Adhemar","family":"Longatto-Filho","sequence":"first","affiliation":[]},{"given":"C\u00e9line","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Olga","family":"Martinho","sequence":"additional","affiliation":[]},{"given":"Marise AR","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Luiz FJ","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Geraldo S","family":"Queiroz","sequence":"additional","affiliation":[]},{"given":"Fernando C","family":"Schmitt","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[]},{"given":"Rui M","family":"Reis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,6,29]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jnci\/djj067","volume":"98","author":"X Castellsague","year":"2006","unstructured":"Castellsague X, Diaz M, de SS, Munoz N, Herrero R, Franceschi S, et al: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006, 98: 303-315.","journal-title":"J Natl Cancer Inst"},{"key":"1546_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ijc.21813","volume":"119","author":"A Chao","year":"2006","unstructured":"Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, et al: Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer. 2006, 119: 91-98. 10.1002\/ijc.21813.","journal-title":"Int J Cancer"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/cncr.11371","volume":"97","author":"JH Farley","year":"2003","unstructured":"Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA: Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer. 2003, 97: 2196-2202. 10.1002\/cncr.11371.","journal-title":"Cancer"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ygyno.2003.08.020","volume":"91","author":"JS Lea","year":"2003","unstructured":"Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO: Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003, 91: 558-562. 10.1016\/j.ygyno.2003.08.020.","journal-title":"Gynecol Oncol"},{"key":"1546_CR5","first-page":"2985","volume":"9","author":"A Dellas","year":"2003","unstructured":"Dellas A, Torhorst J, Gaudenz R, Mihatsch MJ, Moch H: DNA copy number changes in cervical adenocarcinoma. Clin Cancer Res. 2003, 9: 2985-2991.","journal-title":"Clin Cancer Res"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.ygyno.2008.04.016","volume":"110","author":"JM Del Campo","year":"2008","unstructured":"Del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M: Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008, 110: S72-S76. 10.1016\/j.ygyno.2008.04.016.","journal-title":"Gynecol Oncol"},{"key":"1546_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12094-006-0162-1","volume":"8","author":"R Perona","year":"2006","unstructured":"Perona R: Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol. 2006, 8: 77-82. 10.1007\/s12094-006-0162-1.","journal-title":"Clin Transl Oncol"},{"key":"1546_CR8","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1007\/s00018-004-4273-y","volume":"61","author":"Y Kitamura","year":"2004","unstructured":"Kitamura Y, Hirotab S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004, 61: 2924-2931. 10.1007\/s00018-004-4273-y.","journal-title":"Cell Mol Life Sci"},{"key":"1546_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411: 355-365. 10.1038\/35077225.","journal-title":"Nature"},{"issue":"Suppl 1","key":"1546_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-200060001-00002","volume":"60","author":"E Raymond","year":"2000","unstructured":"Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000, 60 (Suppl 1): 15-23. 10.2165\/00003495-200060001-00002.","journal-title":"Drugs"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2165\/00003495-200767140-00006","volume":"67","author":"MF Press","year":"2007","unstructured":"Press MF, Lenz HJ: EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007, 67: 2045-2075. 10.2165\/00003495-200767140-00006.","journal-title":"Drugs"},{"key":"1546_CR12","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1021\/bi00379a035","volume":"26","author":"Y Yarden","year":"1987","unstructured":"Yarden Y, Schlessinger J: Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry. 1987, 26: 1443-1451. 10.1021\/bi00379a035.","journal-title":"Biochemistry"},{"key":"1546_CR13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1358\/mf.2008.30.5.1236622","volume":"30","author":"A Tomillero","year":"2008","unstructured":"Tomillero A, Moral MA: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008, 30: 543-588.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1546_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00535-008-2200-y","volume":"43","author":"Y Kitamura","year":"2008","unstructured":"Kitamura Y: Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol. 2008, 43: 499-508. 10.1007\/s00535-008-2200-y.","journal-title":"J Gastroenterol"},{"key":"1546_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2007.09.017","volume":"108","author":"S Chu","year":"2008","unstructured":"Chu S, Alexiadis M, Fuller PJ: Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol. 2008, 108: 182-190. 10.1016\/j.ygyno.2007.09.017.","journal-title":"Gynecol Oncol"},{"key":"1546_CR16","first-page":"1324","volume":"9","author":"B Sloan","year":"2008","unstructured":"Sloan B, Scheinfeld NS: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008, 9: 1324-1335.","journal-title":"Curr Opin Investig Drugs"},{"key":"1546_CR17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.2174\/092986707782023622","volume":"14","author":"S Schenone","year":"2007","unstructured":"Schenone S, Bondavalli F, Botta M: Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem. 2007, 14: 2495-2516. 10.2174\/092986707782023622.","journal-title":"Curr Med Chem"},{"key":"1546_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ygyno.2008.07.011","volume":"111","author":"O Martinho","year":"2008","unstructured":"Martinho O, Goncalves A, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, et al: KIT activation in uterine cervix adenosquamous carcinomas by KIT\/SCF autocrine\/paracrine stimulation loops. Gynecol Oncol. 2008, 111: 350-355. 10.1016\/j.ygyno.2008.07.011.","journal-title":"Gynecol Oncol"},{"key":"1546_CR19","volume-title":"WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs","author":"FA Tavassoli","year":"2003","unstructured":"Tavassoli FA, Devilee P: WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARC Press"},{"key":"1546_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/pgp.0b013e31802f1996","volume":"26","author":"F Baltazar","year":"2007","unstructured":"Baltazar F, Filho AL, Pinheiro C, Moreira MA, Queiroz GS, Oton GJ, et al: Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol. 2007, 26: 235-241. 10.1097\/pgp.0b013e31802f1996.","journal-title":"Int J Gynecol Pathol"},{"key":"1546_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.2004","volume":"209","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, et al: EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006, 209: 445-453. 10.1002\/path.2004.","journal-title":"J Pathol"},{"key":"1546_CR22","doi-asserted-by":"publisher","first-page":"R788","DOI":"10.1186\/bcr1304","volume":"7","author":"I Carvalho","year":"2005","unstructured":"Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F: Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005, 7: R788-R795. 10.1186\/bcr1304.","journal-title":"Breast Cancer Res"},{"key":"1546_CR23","first-page":"1201","volume":"18","author":"FA Longatto","year":"2007","unstructured":"Longatto FA, Costa SM, Milanezi F, Montruccoli D, Montruccoli GC, Baltazar F, et al: Immunohistochemical expression of VEGF-A and its ligands in non-neoplastic lesions of the breast sampling-assisted by dynamic angiothermography. Oncol Rep. 2007, 18: 1201-1206.","journal-title":"Oncol Rep"},{"key":"1546_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00401-004-0936-x","volume":"109","author":"D Basto","year":"2005","unstructured":"Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, et al: Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (Berl). 2005, 109: 207-210. 10.1007\/s00401-004-0936-x.","journal-title":"Acta Neuropathol (Berl)"},{"key":"1546_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jcp.2007.047043","volume":"61","author":"AL Gomes","year":"2008","unstructured":"Gomes AL, Gouveia A, Capelinha AF, de la CD, Silva P, Reis RM, et al: Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series. J Clin Pathol. 2008, 61: 203-208. 10.1136\/jcp.2007.047043.","journal-title":"J Clin Pathol"},{"key":"1546_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0090-8258(03)00504-3","volume":"91","author":"NH Cho","year":"2003","unstructured":"Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ: P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol. 2003, 91: 346-353. 10.1016\/S0090-8258(03)00504-3.","journal-title":"Gynecol Oncol"},{"key":"1546_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K","volume":"78","author":"GB Kristensen","year":"1996","unstructured":"Kristensen GB, Holm R, Abeler VM, Trope CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 1996, 78: 433-440. 10.1002\/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K.","journal-title":"Cancer"},{"key":"1546_CR28","first-page":"577","volume":"5","author":"AM Kersemaekers","year":"1999","unstructured":"Kersemaekers AM, Fleuren GJ, Kenter GG, Broek Van den LJ, Uljee SM, Hermans J, et al: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999, 5: 577-586.","journal-title":"Clin Cancer Res"},{"key":"1546_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jcp.46.2.149","volume":"46","author":"RJ Hale","year":"1993","unstructured":"Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL: Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol. 1993, 46: 149-153. 10.1136\/jcp.46.2.149.","journal-title":"J Clin Pathol"},{"key":"1546_CR30","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-0497-03","volume":"10","author":"GE Kim","year":"2004","unstructured":"Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, et al: Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 2004, 10: 1366-1374. 10.1158\/1078-0432.CCR-0497-03.","journal-title":"Clin Cancer Res"},{"key":"1546_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/1471-2407-8-232","volume":"8","author":"L Shen","year":"2008","unstructured":"Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, et al: EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer. 2008, 8: 232-10.1186\/1471-2407-8-232.","journal-title":"BMC Cancer"},{"key":"1546_CR32","first-page":"65","volume":"19","author":"T Taguchi","year":"2008","unstructured":"Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D: Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep. 2008, 19: 65-71.","journal-title":"Oncol Rep"},{"key":"1546_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1525-1438.2007.01111.x","volume":"18","author":"H Arias-Pulido","year":"2008","unstructured":"Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, et al: Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer. 2008, 18: 749-754. 10.1111\/j.1525-1438.2007.01111.x.","journal-title":"Int J Gynecol Cancer"},{"key":"1546_CR34","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/JVI.67.8.4521-4532.1993","volume":"67","author":"SW Straight","year":"1993","unstructured":"Straight SW, Hinkle PM, Jewers RJ, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol. 1993, 67: 4521-4532.","journal-title":"J Virol"},{"key":"1546_CR35","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/sj.onc.1208453","volume":"24","author":"B Zhang","year":"2005","unstructured":"Zhang B, Srirangam A, Potter DA, Roman A: HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene. 2005, 24: 2585-2588. 10.1038\/sj.onc.1208453.","journal-title":"Oncogene"},{"key":"1546_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2007.07.057","volume":"108","author":"A Goncalves","year":"2008","unstructured":"Goncalves A, Fabbro M, Lhomme C, Gladieff L, Extra JM, Floquet A, et al: A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008, 108: 42-46. 10.1016\/j.ygyno.2007.07.057.","journal-title":"Gynecol Oncol"},{"key":"1546_CR37","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"20;350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 20;350: 2129-2139. 10.1056\/NEJMoa040938.","journal-title":"N Engl J Med"},{"key":"1546_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1475-2867-6-22","volume":"6","author":"L Taja-Chayeb","year":"2006","unstructured":"Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, Gonzalez-Fierro A, Candelaria M, Chanona-Vilchis J, et al: Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int. 2006, 6: 22-10.1186\/1475-2867-6-22.","journal-title":"Cancer Cell Int"},{"key":"1546_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-8258(03)00081-7","volume":"89","author":"SY Ryu","year":"2003","unstructured":"Ryu SY, Oka K, Tsujii H, Suzuki Y, Nakano T: Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix. Gynecol Oncol. 2003, 89: 414-419. 10.1016\/S0090-8258(03)00081-7.","journal-title":"Gynecol Oncol"},{"key":"1546_CR40","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1371\/journal.pmed.0050019","volume":"5","author":"K Pietras","year":"2008","unstructured":"Pietras K, Pahler J, Bergers G, Hanahan D: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008, 5: e19-10.1371\/journal.pmed.0050019.","journal-title":"PLoS Med"},{"key":"1546_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000119032","volume":"48","author":"S Kummel","year":"2008","unstructured":"Kummel S, Heidecke H, Brock B, Denkert C, Hecktor J, Koninger A, et al: [Imatinib \u2013 a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. Gynakol Geburtshilfliche Rundsch. 2008, 48: 94-100. 10.1159\/000119032.","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"1546_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1365-2559.2003.01644.x","volume":"43","author":"M Stewart","year":"2003","unstructured":"Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, et al: The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology. 2003, 43: 33-39. 10.1046\/j.1365-2559.2003.01644.x.","journal-title":"Histopathology"},{"key":"1546_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/modpathol.3800579","volume":"19","author":"A Giatromanolaki","year":"2006","unstructured":"Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha\/VEGF pathway and unfavourable prognosis. Mod Pathol. 2006, 19: 701-707. 10.1038\/modpathol.3800579.","journal-title":"Mod Pathol"},{"key":"1546_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/path.1520","volume":"202","author":"SB Fox","year":"2004","unstructured":"Fox SB, Turley H, Cheale M, Blazquez C, Roberts H, James N, et al: Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol. 2004, 202: 313-320. 10.1002\/path.1520.","journal-title":"J Pathol"},{"key":"1546_CR45","doi-asserted-by":"publisher","first-page":"e1652","DOI":"10.1371\/journal.pone.0001652","volume":"3","author":"R Shen","year":"2008","unstructured":"Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX: Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE. 2008, 3: e1652-10.1371\/journal.pone.0001652.","journal-title":"PLoS ONE"},{"key":"1546_CR46","unstructured":"A Phase I\/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer. 2008, [ http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00510250 ]"},{"key":"1546_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","volume":"33","author":"S Faivre","year":"2006","unstructured":"Faivre S, Djelloul S, Raymond E: New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol. 2006, 33: 407-420. 10.1053\/j.seminoncol.2006.04.005.","journal-title":"Semin Oncol"},{"key":"1546_CR48","unstructured":"National Ovarian Cancer Coalition Dallas \u2013 Ft Worth Chapter. 2008, [ http:\/\/www.dfwovarian.org\/clinical_trials.html ]"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-212\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T03:34:27Z","timestamp":1589945667000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,29]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-212","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,29]]},"article-number":"212"}}